Science Explorer Back to mapMap

Most cited papers from Mirati Therapeutics (United States)

What are the most cited papers from Mirati Therapeutics (United States)?

The most cited paper from Mirati Therapeutics (United States) is "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients" (Jill F. Hallin et al., 2019), with 1,328 citations. Next come "Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation" (1,051) and "Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor" (754).

Showing 50 of 60 papers. Every paper with more than 29 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients Jill F. Hallin et al. · Cancer Discovery Open access 28 Oct 2019 1,328
2 Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation Pasi Antero Janne et al. · New England Journal of Medicine Open access 3 Jun 2022 1,051
3 Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor Xiaolun Wang et al. · Journal of Medicinal Chemistry Open access 10 Dec 2021 754
4 MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression Mark Magdi Awad, Geoffrey R. Oxnard, David Michael Jackman et al. · Journal of Clinical Oncology Open access 5 Jan 2016 706
5 Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer Jay B. Fell et al. · Journal of Medicinal Chemistry Open access 6 Apr 2020 627
6 Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor Jill F. Hallin et al. · Nature Medicine Oct 2022 549
7 Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C Rona D. Yaeger, Jared Weiss, Meredith S. Pelster et al. · New England Journal of Medicine Open access 21 Dec 2022 524
8 Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber et al. · Journal of Clinical Oncology Open access 6 Apr 2017 475
9 Institutional implementation of clinical tumor profiling on an unselected cancer population Lynette Marie Sholl et al. · JCI Insight Open access 16 Nov 2016 458
10 Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer Samantha B. Kemp et al. · Cancer Discovery Open access 6 Dec 2022 382
11 First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1) Sai‐Hong Ignatius Ou, Pasi Antero Janne, Ticiana A.B. Leal et al. · Journal of Clinical Oncology Open access 15 Feb 2022 316
12 Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation Tanios Bekaii‐Saab, Rona D. Yaeger, Alexander I. Spira et al. · Journal of Clinical Oncology Open access 26 Apr 2023 306
13 Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer Julien Dilly et al. · Cancer Discovery Open access 5 Jul 2024 273
14 MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer Lars D. Engstrom et al. · Cancer Discovery Open access 8 Aug 2023 219
15 NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023 Al B. Benson et al. · Journal of the National Comprehensive Cancer Network Open access Jul 2023 213
16 The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy David M. Briere, Shuai Li, Andrew Calinisan et al. · Molecular Cancer Therapeutics Open access 15 Mar 2021 175
17 Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP -Deleted Cancers Christopher R. Smith et al. · Journal of Medicinal Chemistry Open access 18 Jan 2022 161
18 Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models Lars D. Engstrom et al. · Clinical Cancer Research Aug 2017 150
19 Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer Rona D. Yaeger et al. · Cancer Discovery Open access 10 Nov 2022 148
20 The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy David M. Briere, Niranjan Sudhakar, David Michael Woods et al. · Cancer Immunology Immunotherapy Open access 9 Nov 2017 146
21 Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma Timothy Francis Cloughesy et al. · JAMA Oncology Open access 29 Oct 2020 145
22 KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation Pasi Antero Janne, Igor I. Rybkin, Alexander I. Spira et al. · European Journal of Cancer Oct 2020 141
23 “Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas Rajan Jain, Derek Richard Johnson, Sohil Harshad Patel et al. · Neuro-Oncology Open access 13 Feb 2020 139
24 Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer Joshua K. Sabari, Vamsidhar Velcheti, K. Shimizu et al. · Clinical Cancer Research Open access 11 Apr 2022 135
25 Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer Xinyuan Tong et al. · Cancer Cell Open access 22 Feb 2024 132
26 Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers Jeffrey A. Klomp et al. · Science Open access 6 Jun 2024 121
27 Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial Robert K. Naviaux, Brooke Curtis, Kefeng Li et al. · Annals of Clinical and Translational Neurology Open access 26 May 2017 112
28 Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy Suman Mukhopadhyay et al. · Cancer Research Open access 20 Sep 2023 111
29 Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity Jay B. Fell et al. · ACS Medicinal Chemistry Letters Open access 7 Nov 2018 111
30 A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma Connie Lee Batlevi, Michael Crump, Charalambos Babis Andreadis et al. · British Journal of Haematology Open access 25 Apr 2017 109
31 Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC Kwan Ho Tang, Shuai Li, Alireza Khodadadi-Jamayran et al. · Cancer Discovery Open access 5 Aug 2021 105
32 SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer Hossein Borghaei et al. · Annals of Oncology Open access184 authors 20 Oct 2023 102
33 Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction John M. Ketcham et al. · Journal of Medicinal Chemistry Open access 14 Jul 2022 96
34 TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors A. Cole Edwards, Clint A. Stalnecker, Alexis Jean Morales et al. · Cancer Research Open access 7 Nov 2023 90
35 Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers Erik S. Linklater, Elizabeth A. Tovar, Curt J. Essenburg et al. · Oncotarget Open access 16 Sep 2016 84
36 Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS G12C -Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases Marcelo Vailati Negrao, Alexander I. Spira, Rebecca Suk Heist et al. · Journal of Clinical Oncology Open access 16 Jun 2023 82
37 A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer Anupriya Singhal, Hannah C. Styers, Jonathan Rub et al. · Cancer Discovery Open access 5 Jul 2024 80
38 99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation G.J. Riely, S-H.I. Ou, Igor I. Rybkin et al. · Journal of Thoracic Oncology Open access 27 Mar 2021 80
39 KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation Melissa Lynne Johnson, S.-H.I. Ou, Minal A. Barve et al. · European Journal of Cancer Oct 2020 79
40 Targeting Krasg12c‐mutant cancer with a mutation‐specific inhibitor James G. Christensen, Peter Olson, Tina Marie Briere et al. · Journal of Internal Medicine Open access 16 Mar 2020 76
41 Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma Zhuxuan Li, Xueqian Zhuang, Chun‐Hao Pan et al. · Cancer Discovery Open access 6 Nov 2023 75
42 LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation J.M. Weiss, Rona D. Yaeger, Melissa Lynne Johnson et al. · Annals of Oncology Open access Sep 2021 74
43 A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy Pavlos Msaouel et al. · Science Translational Medicine Open access 20 Apr 2022 67
44 Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia Manoj Kumar Kashyap, Carlos I. Amaya-Chanaga, Deepak Kumar et al. · Journal of Hematology & Oncology Open access 19 May 2017 64
45 Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial Fabrice Barlési et al. · The Lancet 207 authors Aug 2025 60
46 LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation Marina Chiara Garassino, Willemijn S.M.E. Theelen, Robert M. Jotte et al. · Annals of Oncology Open access Oct 2023 54
47 Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study Marc Oliva et al. · Journal for ImmunoTherapy of Cancer Open access Oct 2021 53
48 Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes Petros D. Grivas, Amir Mortazavi, Joel Picus et al. · Cancer Open access 20 Dec 2018 53
49 Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma Jose Antonio Karam et al. · Nature Communications Open access 10 May 2023 49
50 Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis Subrata K. Ghosh, Brian G. Feagan, Elyssa Ott et al. · Journal of Crohn s and Colitis Open access 2 Feb 2024 45

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.